US Patent

US7829574 — Substituted quinazoline compounds and their use in treating angiogenesis-related diseases

Composition of Matter · Assigned to Hutchison Medipharma Enterprises Ltd · Expires 2032-03-23 · 6y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of substituted quinazoline compounds and their use in a pharmaceutical composition for treating angiogenesis-related diseases.

USPTO Abstract

Substituted quinazoline compounds of the following formula: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are defined herein. It also discloses a pharmaceutical composition containing one of these compounds.

Drugs covered by this patent

Patent Metadata

Patent number: US7829574
Jurisdiction: US
Classification: Composition of Matter
Expires: 2032-03-23
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Hutchison Medipharma Enterprises Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.